EcoDrugPlus

Purinergic Receptor P2x 7

Ensembl ID : ENSFHEG00000021691
Gene Symbol: P2RX7
3 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSFHEG00000017580
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSFHEG00000017454
Gene Symbol: P2RY12
3 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSFHEG00000003797
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSFHEG00000000815
Gene Symbol: P2RY4
2 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSFHEG00000003738
Gene Symbol: P2RY6
4 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSFHEG00000005150
Gene Symbol: RAMP1
3 Cross references
190 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSFHEG00000008290
Gene Symbol: RAMP1
3 Cross references
183 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSFHEG00000014819
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-2

Ensembl ID : ENSFHEG00000009522
Gene Symbol: LOC105916087
3 Cross references
199 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSFHEG00000023395
Gene Symbol: LOC105928927
3 Cross references
207 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSFHEG00000003045
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).